Crescendo Biologics has announced the appointment of Dr Michael Booth as Chief Financial Officer. Booth joins with more than 20 years’ experience in biopharmaceutical corporate finance.
The announcement follows the initiation of the company’s Phase Ia/Ib trial for its lead Humabody programme, CB307, a PSMA x CD137 T cell enhancer. Booth will be responsible for Crescendo’s financial strategy and reporting, as well as global investor relations.
Prior to joining Crescendo, Booth served as Division VP, Investor Relations & Corporate Responsibility at Incyte. Before that, he was Senior VP, Communications & Corporate Affairs at Algeta ASA, where he was responsible for corporate communications and capital markets strategies. He has also held pan-European biotechnology equity research roles at Canaccord, Bank of America, and UBS Investment Bank. Booth earned his DPhil in Neuroscience from the University of Oxford and graduated from the University of St Andrews with a BSc in Psychology.
“We are delighted to welcome Mike to the team. His proven track record and wide-ranging financial expertise and relationships will be crucial as Crescendo enters its next phase of growth,” said Theodora Harold, CEO of Crescendo. “We now have a highly experienced team in place, committed to progressing our pipeline of innovative, first-in-class, T cell enhancing programmes. I am confident Mike will add tremendous value as Crescendo looks to achieve its full potential.”
Booth said: “Crescendo is an ambitious company with a unique platform and an innovative pipeline of T cell enhancing therapeutics. This is a very exciting time to join the team, given that the first clinical trial for CB307, the lead Humabody programme, is now underway.”
